Literature DB >> 21392037

An explorative study of low levels of allergen-specific IgE and clinical allergy symptoms during early childhood.

L Söderström1, G Lilja, M P Borres, C Nilsson.   

Abstract

BACKGROUND: Early identification of children at risk for later development of allergic disease is essential for early intervention and initiation of proper treatment and management.
OBJECTIVE: To investigate the relationship between low levels (0.1-0.7 kU(A) /l) of IgE sensitization to food and inhalant allergens and symptoms of eczema, rhinitis, and asthma from birth to 5 years of age.
METHODS: Children (268) were followed prospectively from birth to 5 years of age with physical examinations and measurements of s-IgE at 6, 12, 24, and 60 months of age.
RESULTS: Seventy-four percent of the children with low levels of s-IgE to egg and/or milk at the age of 6 months were still sensitized to one or more allergens at age 2 years. Eighty-four percent of the children with low levels of s-IgE to any of the studied allergens at 12 months of age were still sensitized at age 5. The low levels of egg and milk s-IgE also significantly increased the risk for eczema at the same age and also increased the risk for eczema at 2 years of age.
CONCLUSION: Low levels of s-IgE can be detected from the age of 6 months and are related to further IgE sensitization. The low levels seem to be of importance for both the association to present symptoms and for prediction of future allergic symptoms, especially eczema during early infancy. A detectable s-IgE level, albeit low, could be a clear signal that the immune system is alerted and should be followed.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21392037     DOI: 10.1111/j.1398-9995.2011.02578.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  7 in total

1.  The natural history of egg allergy in an observational cohort.

Authors:  Scott H Sicherer; Robert A Wood; Brian P Vickery; Stacie M Jones; Andrew H Liu; David M Fleischer; Peter Dawson; Lloyd Mayer; A Wesley Burks; Alexander Grishin; Donald Stablein; Hugh A Sampson
Journal:  J Allergy Clin Immunol       Date:  2014-02       Impact factor: 10.793

2.  Allergen Specificity in Specific IgE Cutoff.

Authors:  Ann-Marie Malby Schoos; Simone Møbius Hansen; Frederikke Rosenvinge Skov; Jakob Stokholm; Klaus Bønnelykke; Hans Bisgaard; Bo Lund Chawes
Journal:  JAMA Pediatr       Date:  2020-10-01       Impact factor: 16.193

3.  Component-resolved analysis of IgA, IgE, and IgG4 during egg OIT identifies markers associated with sustained unresponsiveness.

Authors:  B L Wright; M Kulis; K A Orgel; A W Burks; P Dawson; A K Henning; S M Jones; R A Wood; S H Sicherer; R W Lindblad; D Stablein; D Y M Leung; B P Vickery; H A Sampson
Journal:  Allergy       Date:  2016-06-13       Impact factor: 13.146

Review 4.  The Prevalence and Natural History of Food Allergy.

Authors:  Jacob Kattan
Journal:  Curr Allergy Asthma Rep       Date:  2016-07       Impact factor: 4.806

5.  Cutaneous exposure to agglomerates of silica nanoparticles and allergen results in IgE-biased immune response and increased sensitivity to anaphylaxis in mice.

Authors:  Toshiro Hirai; Yasuo Yoshioka; Hideki Takahashi; Ko-ichi Ichihashi; Asako Udaka; Takahide Mori; Nobuo Nishijima; Tokuyuki Yoshida; Kazuya Nagano; Haruhiko Kamada; Shin-ichi Tsunoda; Tatsuya Takagi; Ken J Ishii; Hiromi Nabeshi; Tomoaki Yoshikawa; Kazuma Higashisaka; Yasuo Tsutsumi
Journal:  Part Fibre Toxicol       Date:  2015-06-26       Impact factor: 9.400

6.  Lifetime Increased Risk of Adult Onset Atopic Dermatitis in Adolescent and Adult Patients with Food Allergy.

Authors:  Hsu-Sheng Yu; Hung-Pin Tu; Chien-Hui Hong; Chih-Hung Lee
Journal:  Int J Mol Sci       Date:  2016-12-27       Impact factor: 5.923

7.  Risk factors for recurrent wheezing in infants: a case-control study.

Authors:  Roberta Barros de Sousa; Décio Medeiros; Emanuel Sarinho; José Ângelo Rizzo; Almerinda Rêgo Silva; Ana Carolina Dela Bianca
Journal:  Rev Saude Publica       Date:  2016-05-03       Impact factor: 2.106

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.